Eli Lilly & Co. will spend $5.3 billion to boost production of a key ingredient in its weight-loss and diabetes shots after the treatments’ explosive popularity led to shortages. The ...
Eli Lilly will invest an additional $5.3 billion into a new manufacturing site, boosting production for its weight loss and diabetes medications Mounjaro and Zepbound, the pharmaceutical firm said ...
Eli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its popular weight-loss and diabetes treatments, Zepbound and Mounjaro.
Walmart raised its full-year forecast and reported better-than-expected quarterly results on Thursday, betting that easing ...
, opens new tab to develop cancer therapies, making it eligible for milestone payments of up to $1.1 billion and royalties on sales. The Boston-based drug developer will use its proprietary ...
China gave the greenlight to Eli Lilly & Co.’s blockbuster drug tirzepatide for use in treating diabetes, a move that will intensify the drugmaker’s rivalry with Novo Nordisk A/S over weight ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eli Lilly & Co (LLY – Research Report) and Veeva Systems (VEEV – Research Report). Eli Lilly ...